Roberts Wealth Advisors LLC Purchases 140 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Roberts Wealth Advisors LLC increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 8,157 shares of the medical research company’s stock after purchasing an additional 140 shares during the quarter. Thermo Fisher Scientific makes up 1.6% of Roberts Wealth Advisors LLC’s holdings, making the stock its 20th largest position. Roberts Wealth Advisors LLC’s holdings in Thermo Fisher Scientific were worth $4,857,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of TMO. Virtu Financial LLC acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at about $295,000. Park National Corp OH bought a new position in shares of Thermo Fisher Scientific in the first quarter worth about $207,000. NBC Securities Inc. grew its holdings in shares of Thermo Fisher Scientific by 12.1% during the 1st quarter. NBC Securities Inc. now owns 1,876 shares of the medical research company’s stock valued at $1,191,000 after purchasing an additional 202 shares during the last quarter. Farmers Trust Co. acquired a new position in Thermo Fisher Scientific during the 1st quarter worth approximately $216,000. Finally, New Hampshire Trust boosted its position in Thermo Fisher Scientific by 1.1% in the first quarter. New Hampshire Trust now owns 6,268 shares of the medical research company’s stock valued at $3,643,000 after buying an additional 69 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $180,255.00. Following the transaction, the executive vice president now directly owns 17,887 shares of the company’s stock, valued at $10,747,403.95. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $180,255.00. Following the transaction, the executive vice president now directly owns 17,887 shares of the company’s stock, valued at $10,747,403.95. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Joseph R. Holmes sold 860 shares of the company’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $611.03, for a total transaction of $525,485.80. Following the completion of the sale, the chief accounting officer now directly owns 1,814 shares of the company’s stock, valued at $1,108,408.42. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 23,084 shares of company stock valued at $14,094,292 over the last 90 days. Insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

TMO has been the subject of a number of research reports. Morgan Stanley increased their price target on Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a research note on Friday, September 20th. Raymond James boosted their price objective on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. JPMorgan Chase & Co. lifted their target price on Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an “overweight” rating in a report on Friday, September 20th. Redburn Atlantic began coverage on Thermo Fisher Scientific in a research note on Monday. They issued a “buy” rating and a $680.00 price target for the company. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $767.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday, September 20th. Four investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $656.16.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $600.52 on Wednesday. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64. The firm has a fifty day simple moving average of $607.81 and a two-hundred day simple moving average of $583.76. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $627.88. The firm has a market capitalization of $229.23 billion, a PE ratio of 38.52, a price-to-earnings-growth ratio of 3.80 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. The company had revenue of $10.54 billion for the quarter, compared to analyst estimates of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The firm’s revenue was down 1.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.15 EPS. Analysts forecast that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current fiscal year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.